AU2013251371B2 - Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant Vaccinia virus - Google Patents

Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant Vaccinia virus Download PDF

Info

Publication number
AU2013251371B2
AU2013251371B2 AU2013251371A AU2013251371A AU2013251371B2 AU 2013251371 B2 AU2013251371 B2 AU 2013251371B2 AU 2013251371 A AU2013251371 A AU 2013251371A AU 2013251371 A AU2013251371 A AU 2013251371A AU 2013251371 B2 AU2013251371 B2 AU 2013251371B2
Authority
AU
Australia
Prior art keywords
ser
thr
val
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013251371A
Other languages
English (en)
Other versions
AU2013251371A1 (en
Inventor
Leslie A. Croy
Renee KIRK
Angelika MOKSA
Tracy PANDINA
Mark Paris
Ernest S. Smith
Maurice Zauderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaccinex Inc
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of AU2013251371A1 publication Critical patent/AU2013251371A1/en
Application granted granted Critical
Publication of AU2013251371B2 publication Critical patent/AU2013251371B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2013251371A 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant Vaccinia virus Active AU2013251371B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261639046P 2012-04-26 2012-04-26
US61/639,046 2012-04-26
US201261732776P 2012-12-03 2012-12-03
US61/732,776 2012-12-03
US13/844,388 2013-03-15
US13/844,388 US9708601B2 (en) 2012-04-26 2013-03-15 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
PCT/US2013/038497 WO2013163602A1 (en) 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus

Publications (2)

Publication Number Publication Date
AU2013251371A1 AU2013251371A1 (en) 2014-11-13
AU2013251371B2 true AU2013251371B2 (en) 2018-01-04

Family

ID=49477810

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013251371A Active AU2013251371B2 (en) 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant Vaccinia virus

Country Status (16)

Country Link
US (3) US9708601B2 (https=)
EP (1) EP2841606B1 (https=)
JP (2) JP6498599B2 (https=)
KR (1) KR102108589B1 (https=)
CN (1) CN104520444B (https=)
AU (1) AU2013251371B2 (https=)
CA (1) CA2871597C (https=)
DK (1) DK2841606T3 (https=)
EA (1) EA028164B1 (https=)
ES (1) ES2725673T3 (https=)
IL (1) IL235323B (https=)
NZ (1) NZ630854A (https=)
PL (1) PL2841606T3 (https=)
PT (1) PT2841606T (https=)
SG (1) SG11201406974YA (https=)
WO (1) WO2013163602A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129917A2 (en) 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
AU2012322721B2 (en) 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
AU2015218909A1 (en) * 2014-02-19 2016-08-04 Emergent Biosolutions Canada Inc. Marburg monoclonal antibodies
KR20170019080A (ko) 2015-08-11 2017-02-21 주식회사 엘티전자 플렉시블 사이니지 장치
US10759859B2 (en) 2016-01-14 2020-09-01 Bps Bioscience, Inc. Anti-PD-1 antibodies and uses thereof
US10577427B2 (en) 2016-04-22 2020-03-03 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
BR112019001944A2 (pt) 2016-08-02 2019-05-07 Vaccinex, Inc. métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia
CA3061963A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
CA3177517A1 (en) 2020-05-06 2021-11-11 Ernest S. Smith Integral membrane protein display on poxvirus extracellular enveloped virions
US20240148903A1 (en) * 2021-03-08 2024-05-09 Nanjing GenScript Biotech Co., Ltd. Delivery of antibody by using dual viral vector system
JP2025524372A (ja) 2022-06-10 2025-07-30 バクシネックス インコーポレーティッド 複合膜抗原に特異的な抗体を選択するための方法
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1516932A1 (en) * 2000-04-14 2005-03-23 Transgene S.A. Poxvirus with targeted infection specificity
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
ATE298370T1 (de) 1994-04-29 2005-07-15 Baxter Healthcare Sa Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
ATE407206T1 (de) 1998-11-10 2008-09-15 Univ Rochester Methoden zu herstellung von genbanken
EP1268763A2 (en) 2000-03-28 2003-01-02 University Of Rochester Methods of producing a library and methods of selecting polynucleotides
AU2001297872B2 (en) * 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002062822A2 (en) 2001-02-02 2002-08-15 University Of Rochester Methods of identifying regulator molecules
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1413316A1 (en) 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
AU2004296184B2 (en) 2003-12-04 2010-12-16 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
EP1784196B1 (en) 2004-08-27 2016-12-21 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US7858599B2 (en) 2005-12-30 2010-12-28 Hander Robert W Enhancement of urogenital function
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
AU2008219020B2 (en) 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
CA2710680C (en) 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
CA2725383C (en) * 2008-05-28 2018-09-25 Ruxandra Draghia-Akli Smallpox dna vaccine and the antigens therein that elicit an immune response
WO2010033237A2 (en) 2008-09-22 2010-03-25 Calmune Corporation Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
CN102325875B (zh) 2009-01-08 2018-04-10 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
WO2010129917A2 (en) 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
PT3904391T (pt) * 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
HRP20190047T1 (hr) * 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
NZ605260A (en) 2010-06-14 2013-12-20 Joseph King Allan Anti-vegf antibodies and uses thereof
AR082194A1 (es) * 2010-07-06 2012-11-21 Aveo Pharmaceuticals Inc Anticuerpos anti-ron
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
WO2012006342A2 (en) 2010-07-07 2012-01-12 Albert Einstein College Of Medicine Of Yeshiva University Ceramide-like glycolipid-associated bacterial vaccines and uses thereof
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
MX343640B (es) 2011-05-13 2016-11-15 Nat Univ Corp Tokyo Medical & Dental Univ Promotor de osteogenesis.
AU2012322721B2 (en) 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
NZ629828A (en) 2012-03-02 2017-05-26 Vaccinex Inc Methods for the treatment of b cell-mediated inflammatory diseases
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CN105408355A (zh) 2013-01-31 2016-03-16 瓦克纳斯有限公司 用于提高免疫球蛋白a水平的方法
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
US10577427B2 (en) 2016-04-22 2020-03-03 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
BR112019001944A2 (pt) 2016-08-02 2019-05-07 Vaccinex, Inc. métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia
EP3585435A4 (en) 2017-02-22 2020-12-16 Vaccinex, Inc. EARLY DETECTION OF GLIAL CELL ACTIVATION IN NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISEASES
ES2963046T3 (es) 2017-03-20 2024-03-25 Vaccinex Inc Tratamiento del cáncer con un anticuerpo contra la semaforina-4d combinado con un agente modulador epigenético
CA3061963A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1516932A1 (en) * 2000-04-14 2005-03-23 Transgene S.A. Poxvirus with targeted infection specificity
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies

Also Published As

Publication number Publication date
EP2841606A4 (en) 2015-12-30
JP2019055956A (ja) 2019-04-11
WO2013163602A1 (en) 2013-10-31
US20170306318A1 (en) 2017-10-26
JP6498599B2 (ja) 2019-04-10
PL2841606T3 (pl) 2019-07-31
IL235323A0 (en) 2014-12-31
US9708601B2 (en) 2017-07-18
EA028164B1 (ru) 2017-10-31
US10662422B2 (en) 2020-05-26
EA201491965A1 (ru) 2015-03-31
EP2841606B1 (en) 2019-01-23
CA2871597A1 (en) 2013-10-31
CN104520444B (zh) 2017-12-12
IL235323B (en) 2020-01-30
US9701958B2 (en) 2017-07-11
EP2841606A1 (en) 2015-03-04
ES2725673T3 (es) 2019-09-26
US20160152971A1 (en) 2016-06-02
CN104520444A (zh) 2015-04-15
AU2013251371A1 (en) 2014-11-13
DK2841606T3 (da) 2019-05-06
KR102108589B1 (ko) 2020-05-07
JP2015514811A (ja) 2015-05-21
PT2841606T (pt) 2019-05-17
SG11201406974YA (en) 2014-11-27
US20130288927A1 (en) 2013-10-31
KR20150009560A (ko) 2015-01-26
CA2871597C (en) 2021-04-20
NZ630854A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
AU2013251371B2 (en) Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant Vaccinia virus
KR102564097B1 (ko) 항 gpc3 항체
Moutel et al. NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies
AU2017316604C1 (en) Transgenic non-human animals producing modified heavy chain-only antibodies
TW202542197A (zh) 藉由細胞表現之調控生物活性的抗體
TR201808018T4 (tr) Anti-B7-H3 antikoru.
CN113683697B (zh) 抗b7-h3抗体、其制备方法及用途
CN111448314A (zh) 根据可开发性选择真核细胞展示系统中的多肽药物
CN113164777A (zh) Csf1r/ccr2多特异性抗体
US12577327B2 (en) Mixed binding domains
CN115386006A (zh) 抗gprc5d抗体、其制备方法与用途
TW202346356A (zh) 抗cd3抗體、其製備方法及應用
CN114340737B (zh) 激活性抗gal9结合分子
KR20220087457A (ko) Lif에 특이적인 결합 분자 및 이의 용도
IL309579A (en) VHH-based NKP30 binders
JP5105468B2 (ja) 細胞内で機能する抗体の創製および細胞表現型を制御するタンパク質の同定
WO2025152756A1 (zh) 重组抗fap抗体及其应用
CN115677858A (zh) 一种能够靶向cd137和pd-l1的双特异性抗体的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)